Skip to main content

INMUNOTERAPIA EN CANCER: VACUNACION FRENTE A K-RAS MUTADO

BIO2017-84974-R

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2017
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre UNIVERSIDAD DE VIGO

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Investigo. Repositorio Institucional de la Universidade de Vigo
Publication Artículo científico (JournalArticle)

Synergistic antitumoral effect of epigenetic inhibitors and gemcitabine in pancreatic cancer cells

  • Maietta , Immacolata
  • Martinez Perez, Amparo
  • Álvarez Rodríguez, Maria Rosana
  • Rodríguez de Lera, Ángel
  • González Fernández, Maria Africa
  • Simón Vázquez, Rosana
Epigenetic modifications could drive some of the molecular events implicated in proliferation, drug resistance and metastasis of pancreatic ductal adenocarcinoma (PDAC). Thus, epigenetic enzyme inhibitors could be the key to revert those events and transform PDAC into a drug-sensitive tumor. We performed a systematic study with five different epigenetic enzyme inhibitors (1, UVI5008, MS275, psammaplin A, and BIX01294) targeting either Histone Deacetylase (HDAC) 1 or 1/4, DNA methyltransferase 3a (DNMT3a), Euchromatic histone lysine methyltransferase 2 (EHMT2), or Sirtuin 1 (SIRT1), as well as one drug that restores the p53 function (P53R3), in three different human PDAC cell lines (SKPC-1, MIA PaCa-2, and BxPC-3) using 2D and 3D cell cultures. The synergistic effect of these antitumoral drugs with gemcitabine was tested and the most efficient combinations were characterized by RNA-seq. The inhibition of HDAC1/4 (MS275), HDAC1/4/SIRT1/DNMT3a (UVI5008) or EHMT2 (BIX01294) induced a significant reduction on the cell viability, even in gemcitabine-resistance cells. The combination of UVI5008 or MS275 with gemcitabine induced a synergistic effect at low concentration and the RNA-Seq analysis revealed some synergy candidate genes as potential biomarkers. Reverting aberrant epigenetic modifications in combination with gemcitabine offers an alternative treatment for PDAC patients, with an important reduction of the therapeutic dose., Xunta de Galicia | Ref. ED431C 2020/02, Xunta de Galicia | Ref. ED431G2019/06, Ministerio de Economía, Industria y Competitividad | Ref. BIO2017-84974-R, Xunta de Galicia | Ref. ED481A-2021/364, Xunta de Galicia | Ref. ED481A-2018/230, Ministerio de Economía, Industria y Competitividad | Ref. PID2019-107855RB-I00, Xunta de Galicia | Ref. ED431C 2017/61
Investigo. Repositorio Institucional de la Universidade de Vigo
Publication Artículo científico (JournalArticle)

Immunization with nanovaccines containing mutated K-Ras peptides and imiquimod aggravates heterotopic pancreatic cancer induced in mice

  • Martinez Perez, Amparo
  • Diego González, Lara
  • Vilanova, Manuel
  • Correia, Alexandra
  • Simón Vázquez, Rosana
  • González Fernández, Maria Africa
Purpose: The growing incidence and lethality of pancreatic cancer urges the development of new therapeutic approaches. Anti-tumoral vaccines can potentiate the immune response against the tumor, targeting specific antigens expressed only on tumor cells. In this work, we designed new vaccines for pancreatic cancer, composed by chitosan nanocapsules (CS NCs) containing imiquimod (IMQ) as adjuvant, and targeting the K-Ras mutation G12V. Experimental design: We tested the immunogenicity of our vaccines in mice, carrying different combinations of K-Ras mutated peptides. Then, we analyzed their prophylactic and therapeutic efficacy in mice bearing heterotopic pancreatic cancer. Results: Unexpectedly, although good results were observed at short time points, the different combinations of our CS NCs vaccines seemed to potentiate tumor growth and reduce survival rate. We propose that this effect could be due to an inadequate immune response, partially because of the induction of a regulatory tolerogenic response. Conclusion: Our results call for caution in the use of some NCs containing IMQ in the immunotherapy against pancreatic cancer., Agencia Estatal de Investigación | Ref. BIO2017-84974-R, Xunta de Galicia | Ref. ED431C 2020/02, Xunta de Galicia | Ref. ED431G2019/06, Xunta de Galicia | Ref. ED481A-2018/230, Xunta de Galicia | Ref. ED481A-2018/294
Investigo. Repositorio Institucional de la Universidade de Vigo
Publication Artículo científico (JournalArticle)

Nanoparticles and trained immunity: glimpse into the future

  • Magadán Mompó, Susana
  • Mikelez Alonso, Idoia
  • Borrego, Francisco
  • González Fernández, Maria Africa
Financiado para publicación en acceso aberto: Universidade de Vigo/CISUG, Emerging evidences show that innate immune cells can display changes in their functional programs after infection or vaccination, which lead to immunomodulation (increased or reduced responsiveness) upon secondary activation to the same stimuli or even to a different one. Innate cells acquire features of immunological memory, nowadays using the new term of "trained immunity" or "innate immune memory", which is different from the specific memory immune response elicited by B and T lymphocytes. The review focused on the concept of trained immunity, mostly on myeloid cells. Special attention is dedicated to the pathogen recognition along the evolution (bacteria, plants, invertebrate and vertebrate animals), and to techniques used to study epigenetic reprogramming and metabolic rewiring. Nanomaterials can be recognized by immune cells offering a very promising way to learn about trained immunity. Nanomaterials could be modified in order to immunomodulate the responses ad hoc. Many therapeutic possibilities are opened, and they should be explored., Xunta de Galicia | Ref. GRC-ED431C 2020/02, Agencia Estatal de Investigación | Ref. BIO2017-84974-R, Asociación Española Contra el Cáncer | Ref. PROYE16074BORR, Departamento de Salud del Gobierno Vasco | Ref. 2020333024
Investigo. Repositorio Institucional de la Universidade de Vigo
Publication Artículo científico (JournalArticle)

Human immunology and immunotherapy: main achievements and challenges

  • Varade Lopez, Jezabel
  • Magadán Mompó, Susana
  • González Fernández, Maria Africa
The immune system is a fascinating world of cells, soluble factors, interacting cells, and tissues, all of which are interconnected. The highly complex nature of the immune system makes it difficult to view it as a whole, but researchers are now trying to put all the pieces of the puzzle together to obtain a more complete picture. The development of new specialized equipment and immunological techniques, genetic approaches, animal models, and a long list of monoclonal antibodies, among many other factors, are improving our knowledge of this sophisticated system. The different types of cell subsets, soluble factors, membrane molecules, and cell functionalities are some aspects that we are starting to understand, together with their roles in health, aging, and illness. This knowledge is filling many of the gaps, and in some cases, it has led to changes in our previous assumptions; e.g., adaptive immune cells were previously thought to be unique memory cells until trained innate immunity was observed, and several innate immune cells with features similar to those of cytokine-secreting T cells have been discovered. Moreover, we have improved our knowledge not only regarding immune-mediated illnesses and how the immune system works and interacts with other systems and components (such as the microbiome) but also in terms of ways to manipulate this system through immunotherapy. The development of different types of immunotherapies, including vaccines (prophylactic and therapeutic), and the use of pathogens, monoclonal antibodies, recombinant proteins, cytokines, and cellular immunotherapies, are changing the way in which we approach many diseases, especially cancer., Agencia Estatal de Investigación | Ref. BIO2017-84974-R, Xunta de Galicia | Ref. ED431C 2016/041, Xunta de Galicia | Ref. ED431G2019/06, Unión Europea | Ref. INTERREG V-A España-Portugal (POCTEP) 2014-2020
Investigo. Repositorio Institucional de la Universidade de Vigo
Publication Artículo científico (JournalArticle)

Combined inhibition of FOSL-1 and YAP using siRNA-lipoplexes reduces the growth of pancreatic tumor

  • Diego González, Lara
  • Fernández Carrera, Andrea
  • Igea Fernandez, Ana
  • Martinez Perez, Amparo
  • Real Oliveira, M. Elisabete C. D.
  • Gomes, Andreia C.
  • Guerra, Carmen
  • Barbacid, Mariano
  • González Fernández, Maria Africa
  • Simón Vázquez, Rosana
Pancreatic cancer evades most of the current therapies and there is an urgent need for new treatments that could efficiently eliminate this aggressive tumor, such as the blocking of routes driving cell proliferation. In this work, we propose the use of small interfering RNA (siRNA) to inhibit the combined expression of FOSL-1 and YAP, two signaling proteins related with tumor cell proliferation and survival. To improve the efficacy of cell transfection, DODAB:MO (1:2) liposomes were used as siRNA nanocarriers, forming a complex denominated siRNA-lipoplexes. Liposomes and lipoplexes (carrying two siRNA for each targeted protein, or the combination of four siRNAs) were physico-chemically and biologically characterized. They showed very good biocompatibility and stability. The efficient targeting of FOSL-1 and YAP expression at both mRNA and protein levels was first proved in vitro using mouse pancreatic tumoral cell lines (KRASG12V and p53 knockout), followed by in vivo studies using subcutaneous allografts on mice. The peri-tumoral injection of lipoplexes lead to a significant decrease in the tumor growth in both Athymic Nude-Foxn1nu and C57BL/6 mice, mainly in those receiving the combination of four siRNAs, targeting both YAP and FOSL-1. These results open a new perspective to overcome the fast tumor progression in pancreatic cancer., Xunta de Galicia | Ref. ED431C 2020/02, Xunta de Galicia | Ref. ED431G2019/06, Ministerio de Ciencia, Innovación y Universidades | Ref. RTI2018-094664-B-I00, Ministerio de Economía, Industria y Competitividad | Ref. BIO2017-84974-R